Title:
METHOD FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
Document Type and Number:
Japanese Patent JP2014129362
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide an improved method for the synthesis of erlotinib (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine) and its pharmaceutically acceptable salts.SOLUTION: A method comprises reacting a 4-halo-6,7-bis(2-methoxyethoxy) quinazoline with 3-aminophenyl acetylene or a salt thereof under acidic conditions where an acid is used which may be selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, p-toluene sulfonic acid, benzoic acid, citric acid, succinic acid, oxalic acid, benzene sulfonic acid, tartaric acid, methane sulfonic acid, phosphoric acid and mixtures thereof, thereby forming the corresponding acid salt of erlotinib shown in formula described below.
Inventors:
DHARMARAJ RAMACHANDRA RAO
RAJENDRA NARAYANRAO KANKAN
RAJENDRA NARAYANRAO KANKAN
Application Number:
JP2014018797A
Publication Date:
July 10, 2014
Filing Date:
February 03, 2014
Export Citation:
Assignee:
CIPLA LTD
International Classes:
C07D239/94; A61K31/517; A61P43/00; C07B61/00
Domestic Patent References:
JPH10506633A | 1998-06-30 | |||
JP2002513009A | 2002-05-08 |
Other References:
C.G.WERMUTH編, 「最新 創薬化学 下巻」, vol. 347〜365頁, JPN6014029314, 1999, ISSN: 0002974777
TIMOTHY NORRIS, JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2, vol. V12, JPN5010004112, 2000, pages 2498 - 2502, ISSN: 0002974778
TIMOTHY NORRIS, JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2, vol. V12, JPN5010004112, 2000, pages 2498 - 2502, ISSN: 0002974778
Attorney, Agent or Firm:
Kurata Masatoshi
Yoshihiro Fukuhara
Nobuhisa Nogawa
Takashi Mine
Naoki Kono
Katsu Sunagawa
Morisezo Iseki
Tatsushi Sato
Takashi Okada
Mihoko Horiuchi
Yoshihiro Fukuhara
Nobuhisa Nogawa
Takashi Mine
Naoki Kono
Katsu Sunagawa
Morisezo Iseki
Tatsushi Sato
Takashi Okada
Mihoko Horiuchi
Previous Patent: 空気調和装置
Next Patent: USE OF SECRETOR, LEWIS AND SIALYL ANTIGEN LEVELS IN CLINICAL SAMPLES AS PREDICTORS OF RISK FOR DISEA...
Next Patent: USE OF SECRETOR, LEWIS AND SIALYL ANTIGEN LEVELS IN CLINICAL SAMPLES AS PREDICTORS OF RISK FOR DISEA...